Thirdly, multi centre clinical trials are indicated to evaluate the synergistic therapeutic effects of targeted combination strategies, such as PCSK9 + CXCL12, with a particular focus on differential treatment outcomes in patients exhibiting metabolic abnormalities, including diabetes and obesity. This evidence concerns the gene CXCL12 and obesity due to melanocortin 4 receptor deficiency.